The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47).
 
Jonny Finlay
Employment - Granular Therapeutics; LockBody Therapeutics; RxBiologics; UltraHuman; UltraHuman8; WJFinlay Consulting
Leadership - Granular Therapeutics; LockBody Therapeutics; RxBiologics; UltraHuman; UltraHuman8; WJFinlay Consulting
Stock and Other Ownership Interests - Granular Therapeutics; LockBody Therapeutics; Pfizer; RxBiologics; UltraHuman; UltraHuman8; WJFinlay Consulting; WJFinlay Consulting (I)
Patents, Royalties, Other Intellectual Property - Granular Therapeutics; LockBody Therapeutics; Pfizer; UltraHuman; UltraHuman8; Villaris Therapeutics
Other Relationship - Granular Therapeutics; LockBody Therapeutics; Pfizer; UltraHuman; UltraHuman8; Villaris Therapeutics; WJFinlay Consulting
 
Antoine Yver
Employment - Centessa Pharmaceuticals; Daiici Sankyo Inc
Leadership - Centessa Pharmaceuticals
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Sanofi
Expert Testimony - Daiichi Sankyo/Astra Zeneca
 
Simon Chivers
Stock and Other Ownership Interests - ADC Therapeutics; AstraZeneca
Consulting or Advisory Role - LockBody Therapeutics
 
David Grainger
Employment - A Bio Limited; ApcinteX; Barkway House Estates; BHE Altair; BHE Betelgeuse; BHE Capella; BHE Deneb; C21MED I LLP; Centessa Pharmaceuticals; Critical Pressure Limited; DC Europa Limited; Hydrogen Therapeutics Limited; Imhotex; Inexia; Janpix Limited/Centessa Pharmaceuticals; Lithium Tx Limited; LockBody Therapeutics; Methuselah Health; Orexia Therapeutics; Pandeia Therapeautics; Perfect Balance Bio Limited; Proteomx Limited; Round Earth Therapeutics; RxBiologics; RxCelerate; RxCelerate (I); SDS Therapeutics Limited; The Cambridge Partnership; The Foundry (Cambridge) Ltd; The Foundry (Cambridge) Ltd (I); Total Medical Ventures; Ultrahuman Four Limited; Ultrahuman Two Limited; Z Factor
Leadership - Centessa Pharmaceuticals; RxCelerate; RxCelerate (I); The Foundry (Cambridge) Ltd; The Foundry (Cambridge) Ltd (I)
Stock and Other Ownership Interests - Centessa Pharmaceuticals; DC Europa Limited; Elements Squared Group; GlaxoSmithKline (I); Imhotex; Medicxi Ventures; Methuselah Health; Morphogen-IX; Perfect Balance Bio Limited; Round Earth Therapeutics; RxCelerate; RxCelerate (I); The Foundary (Cambridge) Ltd; Total Medical Ventures; Total Medical Ventures (I); Z Factor
Consulting or Advisory Role - Centessa Pharmaceuticals; Critical Pressure Limited; DC Europa Limited; Imhotex; Medicxi Ventures; Methuselah Health; Morphogen-IX; Pandeia Therapeautics; Perfect Balance Bio Limited; Round Earth Therapeutics; Z Factor
Patents, Royalties, Other Intellectual Property - DC Europa Limited; Elements Squared Group; Medicxi Ventures; Morphogen-IX; Z Factor
Other Relationship - Janpix; LockBody Therapeutics; Orexia Therapeutics; RxBiologics; The Cambridge Partnership